Drug Buyers 'Astounded' As Celgene Axes $55M Antitrust Deal
By Adam Lidgett ( January 8, 2020, 7:59 PM EST) -- Bristol-Myers Squibb's Celgene unit has dropped out of a $55 million deal that would have ended litigation alleging a sweeping scheme to monopolize the market for two cancer drugs that have racked up tens of billions of dollars in sales....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.